ZA200903854B - A gastroretentive pharmaceutical dosage form - Google Patents

A gastroretentive pharmaceutical dosage form

Info

Publication number
ZA200903854B
ZA200903854B ZA2009/03854A ZA200903854A ZA200903854B ZA 200903854 B ZA200903854 B ZA 200903854B ZA 2009/03854 A ZA2009/03854 A ZA 2009/03854A ZA 200903854 A ZA200903854 A ZA 200903854A ZA 200903854 B ZA200903854 B ZA 200903854B
Authority
ZA
South Africa
Prior art keywords
dosage form
pharmaceutical dosage
gastroretentive pharmaceutical
gastroretentive
pharmaceutical
Prior art date
Application number
ZA2009/03854A
Other languages
English (en)
Inventor
Murphy Caragh Yahya
Viness Choonara Pilay
Sarashnee Moomisami
Original Assignee
Univ Of The Witwatesrand Johannesburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of The Witwatesrand Johannesburg filed Critical Univ Of The Witwatesrand Johannesburg
Publication of ZA200903854B publication Critical patent/ZA200903854B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2009/03854A 2008-06-19 2009-05-29 A gastroretentive pharmaceutical dosage form ZA200903854B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA200710997 2008-06-19

Publications (1)

Publication Number Publication Date
ZA200903854B true ZA200903854B (en) 2011-02-23

Family

ID=44309136

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/03854A ZA200903854B (en) 2008-06-19 2009-05-29 A gastroretentive pharmaceutical dosage form

Country Status (5)

Country Link
US (1) US8778396B2 (cg-RX-API-DMAC7.html)
EP (1) EP2306983A1 (cg-RX-API-DMAC7.html)
JP (1) JP5560268B2 (cg-RX-API-DMAC7.html)
WO (1) WO2009153632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903854B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914080A2 (pt) * 2008-10-08 2015-10-27 Bioplus Life Sciences Pvt Ltda "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
WO2011053917A2 (en) * 2009-11-01 2011-05-05 Adeona Pharmaceuticals, Inc. Gastroretentive oral high dose zinc preparations
EP2444064A1 (en) * 2010-10-22 2012-04-25 Meliatys Process for making multiparticulate gastroretentive dosage forms
US8589775B2 (en) * 2011-03-14 2013-11-19 Infineon Technologies Ag Error tolerant flip-flops
CN104666267B (zh) * 2015-03-27 2017-08-08 康普药业股份有限公司 一种阿昔洛韦药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
JP7418958B2 (ja) * 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
EP4534527A3 (en) 2017-09-20 2025-06-18 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
IL275444B2 (en) * 2017-12-18 2025-01-01 Tris Pharma Inc Modified release drug powder formulation containing gastric-retaining raft-forming systems with pulsed drug release
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN112469400A (zh) * 2018-06-19 2021-03-09 新加坡国立大学 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂
CN109925289B (zh) * 2019-04-11 2021-05-25 海南普利制药股份有限公司 地氯雷他定分散片
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
MX2024001390A (es) 2021-07-30 2024-05-17 Evecxia Therapeutics Inc Formas de dosificacion gastrorretentivas de 5-hidroxitriptofano.
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
TR200100731T2 (tr) * 1998-09-14 2001-06-21 Ranbaxy Laboratories Limited Geçici ve aralıklı kontrol sağlayan, oral yoldan kontrollü ilaç verme sistemi
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US7674480B2 (en) 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20050064027A1 (en) * 2001-12-15 2005-03-24 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
JP2004002320A (ja) * 2002-03-04 2004-01-08 Medorekkusu:Kk 生体内で相転移する液状マトリックスおよび液状経口製剤
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
EP1729741A2 (en) 2004-03-03 2006-12-13 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
BRPI0612594A2 (pt) * 2005-06-29 2010-11-23 Panacea Biotec Ltd composições farmacêuticas de liberação modificada e processo de pereparação das mesmas
WO2007106957A1 (en) * 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof

Also Published As

Publication number Publication date
US8778396B2 (en) 2014-07-15
JP5560268B2 (ja) 2014-07-23
US20110182988A1 (en) 2011-07-28
WO2009153632A1 (en) 2009-12-23
JP2012504551A (ja) 2012-02-23
EP2306983A1 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
ZA200903854B (en) A gastroretentive pharmaceutical dosage form
IL207128A0 (en) Pharmaceutical dosage form
AP2010005341A0 (en) Solid pharmaceutical dosage form
IL206159A0 (en) Oral pharmaceutical dosage forms
ZA201304709B (en) A pharmaceutical dosage form
SI2399579T1 (sl) Farmacevtske odmerne oblike
GB0703507D0 (en) Solid pharmaceutical dose
IL216256A0 (en) A pharmaceutical composition
GB0801416D0 (en) Pharmaceutical compounds
SI2285413T1 (sl) Farmacevtski sestavek
ZA200903858B (en) Pharmaceutical dosage form
ZA201104348B (en) Pharmaceutical preparation
GB0710439D0 (en) Oral dosage form
IL200619A0 (en) Novel dosage form
GB0712389D0 (en) A Pharmaceutical composition
GB0806527D0 (en) Pharmaceutical compounds
IL219617A0 (en) Pharmaceutical solid dosage form
GB0815972D0 (en) Pharmaceutical preparation
ZA201008115B (en) A solid pharmaceutical formulation
IL245577A0 (en) Dose unit of efdanosone
GB0822124D0 (en) Oral dosage form
PL2309992T3 (pl) Kompozycja farmaceutyczna zawierająca statynę
ZA200903855B (en) A pharmaceutical dosage form
GB0820625D0 (en) A medicament
GB0802576D0 (en) Dosage form